1. In Vivo
  2. >>Innovation

Singulex: Next-Gen Immunodiagnostics

 
• By Peter Charlish

Singulex originally developed its Single Molecule Counting technology for research applications, but it is poised to launch a clinical diagnostics tool that incorporates the highly sensitive technology.

Singulex Inc., the privately held immunodiagnostics company based in Alameda, CA, is close to market launch of its Clarity in vitro diagnostic system. The fully automated platform is designed to bring the benefits of the company’s Single Molecule Counting (SMC) technology to hospital and reference laboratories.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Building The Worm Atlas For I&I Breakthroughs

 
• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

BioBytes: AI-Related Deals In Q1 2025

 
• By David Wild

AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Antag Therapeutics: Developing Peptide-Based Treatments For Obesity Management

 
• By Jo Shorthouse

Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By Brian Yang

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By Jo Shorthouse

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By Jo Shorthouse

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.